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ABSTRACT
Using pulmonary tuberculosis (pTB) as an example of a vaccine-preventable disease (VPD), we aimed to gather 
evidence on the economic impact of treating a case or managing an outbreak of a VPD. A scoping review was con-
ducted. Online databases (MEDLINE and Google Scholar) were used to collate published studies from the year 2015 
to 2019 on the management cost of one case or an outbreak of pTB. Keywords used were cost, treatment, outbreak, 
pulmonary tuberculosis, tuberculosis, economic, economic evaluation. A total of 29 studies were analysed. The 
costs of pTB treatment for individual patient were higher in high-income countries compared to middle-income and 
low-income countries. A case of pTB can result in household catastrophic health expenditure; while an outbreak can 
overwhelm the health system’s capacity, and disrupts the economy of a country. Therefore, accessibility of vaccines 
especially in low-income countries must be ensured. Also, vaccine-hesitant individuals must reconsider their stance 
on vaccination. 
 
Keywords:  Vaccine-preventable diseases, Pulmonary tuberculosis, Economic impact, Vaccine hesitancy
Corresponding Author:  
Aidalina Mahmud, PhD
Email: aidalina@upm.edu.my
Tel: +603-9769 2940
INTRODUCTION
As of October 2010, there are 11 diseases that are part 
of the recommended childhood immunization schedule 
from birth to 18 years.  The main vaccine-preventable 
diseases (VPDs) targeted by the Expended Program on 
Immunization (EPI) are tuberculosis (TB), diphtheria, 
tetanus, pertussis, measles, hepatitis B, rotavirus, 
Haemophilus influenzae type B (Hib), Streptococcus 
Pneumoniae infection and yellow fever. 
According to the World Health Organization (WHO), 
in 2017 there was an estimated 19.9 million infants 
worldwide who did not receive routine immunization 
services such as three doses of the diphtheria, tetanus and 
pertussis (DTP) vaccine (1). Apart from the recognized 
problems of access to vaccines in low-income countries, 
there seems to be a new worrying trend globally, which 
is vaccine hesitancy (2,3). The WHO in 2019 declared 
it as one of the Ten Threats of Health (4). The WHO 
defines vaccine hesitancy as the “reluctance or refusal 
to vaccinate despite the availability of vaccines” (3). 
Vaccine hesitancy can contribute to reduced population 
immunity (or herd immunity), which may result in 
localized outbreaks or cases of infection in specific 
groups or populations (7). Regardless of the reasons of 
no vaccination, the economic costs of managing a case 
of VPDs is high. Moreover, because VPDs are infectious 
diseases, their management not only involves the 
patient, but also the contacts and ultimately the nation. 
The management of any disease incurs costs, hence 
preventing people from contracting the disease should 
be the way forward, as in the case of VPDs. Perhaps 
if the providers of vaccines and the users are aware of 
the real-life economic impact of not being vaccinated, 
this knowledge could be one of the encouraging factors 
in overcoming the inaccessibility of vaccines and/or the 
hesitancy in using vaccines.
Therefore, using pulmonary tuberculosis (pTB) as an 
example of a VPD, we conducted a scoping review 
to identify and map the available evidence on the 
economic impact of treating a case or in managing an 
outbreak of pTB. Specific question was:  What are the 
economic costs and impact, of managing one case of 
TB, or its outbreak to a community and/or country? 
METHODS
This review considered published studies on the 
cost incurred in the management of one pTB case or 
255
Malaysian Journal of Medicine and Health Sciences (eISSN 2636-9346)
Mal J Med Health Sci 16(2): 254-261, May 2020
an outbreak of pTB. The design of the search strategy 
was done according to the broad Population-Concept-
Context (PCC) mnemonic recommended by the Joanna 
Briggs Institute for scoping reviews (8). Population was 
cases of pTB of any nation, sex and age; Concept was 
the cost of treating pTB in the specified currency, while 
Context was the perspective of the economic evaluation, 
be it providers’, patient’s or societal. Keywords used for 
the review were cost, treatment, outbreak, pulmonary 
tuberculosis, tuberculosis, economic, economic 
evaluation.
This review consists of three steps. The first step was 
literature search in databases MEDLINE and Google 
Scholar, followed by an analysis of the words contained 
in the title and abstract. The second step was screening 
of the full text versions of the articles two reviewers 
separately, to determine whether the articles fulfilled the 
inclusion criteria. Disagreements of the decisions were 
resolved through discussion (4). Thirdly, the reference 
lists of all articles were hand-searched for additional 
studies. Papers found through snowballing of eligible 
systematic reviews were also screened and subsequently 
reviewed.
Eligibility criteria
The inclusion criteria were aimed to find only published 
studies and papers (of which full-text journal articles 
were available), limited to materials in the English 
language and published between the years 2005 and 
2019. Editorials, articles on methodological aspects, 
protocols, reviews, replies, comments, correspondences, 
conference proceedings, viewpoints, and protocols 
were excluded.
Study selection
After the reviewers independently assessed the titles 
and abstracts, eligible full-text articles were retrieved 
and again screened against the inclusion criteria. Any 
disagreements were resolved through discussion or 
involvement of a third reviewer (2). 
Data charting
Methodological features were extracted into the 
adapted JBI Template Study Details, Characteristics and 
Results Extraction Instrument (JBI Reviewer’s Manual) 
(9). The study details charted were citation details (e.g. 
author/s, year of publication, country), population (study 
population and the conduct of the study), concept (the 
cost of treating pTB in the specified currency) and context 
of costs (perspective of the economic evaluation).
Costs remained in local currencies of the year of the 
study or US dollars (USD) as reported by the original 
researchers. To put the costs into perspective, some 
costs were compared against the GDP per capita of the 
country in which the study was conducted, adjusted to 
the year of the currency of the cost in the study. 
RESULTS
Study characteristics
Systematic searches yielded 423 records. After the 
assessment, a total of 29 studies were included in 
the final analysis. All studies were cross-sectional 
studies, either using prospective and retrospective data 
collection method. Several studies used secondary data. 
The outcomes of the evaluations were either the cost 
of treatment per patient, the costs of management of 
one out-break or the incidence of catastrophic health 
expenditure, as summarized in Table I.
Based on the findings of the reviewed studies, the costs 
of pTB treatment for individual patient in high-income 
countries ranged from 17% to more than 60% of the 
countries’ per capita growth domestic product (GDP). 
For example, in the United States of America (USA), 
a study found that the costs of treating and managing 
cases of active pTB disease was United States Dollar 
(USD) 34,600 in 2015 which was more than half (61%) 
of the per capita GDP the country in that same year (5). 
Another study in the USA, the average hospitalization 
expenditure for pTB disease per person (including 
multiple hospitalization episodes) among privately 
insured patients was USD 28, 058 (also almost 60% of 
the per capita GDP) (6). In Cyprus, pTB treatment per 
person was €12,882 estimated at approximately 52% of 
their GDP per capita (7). Similarly, in Spain, the mean 
cost of treatment of a patient involving both direct and 
indirect costs from diagnosis to rehabilitation in 2014 
was € 10,262 (almost 50% of their per capita GDP) (10). 
In Germany, the mean outpatient costs per case were 
€11,240 (about 28% of their per capita GDP) (11). In 
Australia the median cost of treating drug susceptible 
pulmonary pTB was AUD 11,538 (approximately 17% 
of the per capita GDP) (12). 
As for the middle- and low-income countries, based 
on the findings of the studies reviewed, treatment of 
individual pTB cases in these countries constitute lesser 
percentage of the countries’ GDP. In Iran, treatment 
cost per person was USD 2,588 in the year 2011 
(approximately 38% of their GDP per capita) and USD 
1,409 in the year 2015 (approximately 26% of their 
GDP per capita) (13,14). 
The pTB treatment costs were found to be lower in 
Yemen at USD 142 (approximately 11% of their GDP per 
capita (15). In China the average total cost of inpatient 
was CNY13007 (approximately 27% of their GDP per 
capita) (16), while in Malaysia, one study showed that 
the cost of pTB treatment was USD 726 (9.9% of their 
GDP per capita) (17), while another study showed that it 
was USD 916 (18). 
The costs of TB treatment for individual patient were 
higher in high-income countries, which ranged 
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Table I:  Cost of pTB treatment
Country, 
year
Study population and the conduct of the study Perspective Cost, (currency year) Note
United States 
of America, 
2017 (5)
Systematic review of the United States of America 
(USA) literature.
Estimated costs of treating and managing cases of 
active TB disease in California, based on published 
figures in the USA and operational data of the 
California Department of Public Health.
Provider Average direct cost of treating and managing a 
TB case = US$34,600 (range of average 16,600–
61,300), (year 2015).
United States 
of America, 
2017 (6)
Retrospective review of in-patient claims data on 
private insurance claims for reimbursement for TB 
hospital admissions in the 2010-2014 MarketScan® 
commercial database.
Estimated the hospitalization expenditures 
for tuberculosis (TB) disease among privately 
insured patients in the United States
Patient Average hospitalization expenditure per person 
(including multiple hospitalizations) = USD 
28 058 (95%CI USD 26 632-USD 29 484), (year 
2014).
Cyprus, 2018 
(7)
A retrospective probabilistic incidence-based cost 
of illness model developed to calculate direct 
medical and non-medical costs and indirect costs,
Estimated the economic burden of tuberculosis in 
Cyprus during 2009.
Societal Mean per patient cost = €12,882 (95% CI: 
€12,747.35 – €12,964.32), (year 2009) 
Direct medical costs = €10,675 per patient (95% 
CI: €10,462.07 – €10,780.59) 
Indirect cost was €1,820 (95% CI: €1,815.20 – 
€1,873.65).
Direct medical costs accounted for 
83.07% of the overall expenses per 
patient.  
Total direct non-medical costs accounted 
for 2.77% of the overall expenses 
whereas 14.16% of the overall expenses 
were associated with the indirect cost.
Spain, 2016 
(8)
Prospective multi-centre study.
Determined the direct (hospital stays, visits, 
diagnostic tests, and treatment) and indirect (sick 
leave and loss of productivity, contact tracing, and 
rehabilitation) costs of pulmonary TB patients.
Societal Average total cost = €10,262.62 ±14,961.66, 
(year 2014-2015)
Costs increased significantly when 
associated with hospital admission, 
polymerase chain reaction, sputum 
smears and cultures, sensitivity testing, 
chest computed tomography, pleural 
biopsy, drug treatment longer than nine 
months, DOT and sick leave. 
Germany, 
2012 (9)
Retrospective review of documents to estimate 
the mean direct outpatient and combined in- and 
outpatient costs of TB, and other attributable costs 
of the disease.
Calculations of the direct costs are based on the 
rates established by the uniform appraisal scale and 
Institute for the Hospital Remuneration System data 
for the German diagnosis-related groups (DRG) 
system.
Society The outpatient costs (rounded) per case = 
€1,197 (adults) and €1,006 (children) for 
standard therapy (year 2011).
The combined in-patient/outpatient costs 
= €7,364 (adults) and €7,300 (children), 
respectively (year 2011).
The costs due to loss of productivity = 
€2,313. 
Costs per case for rehabilitation = €74
Cost for contact tracing = €922.
Australia, 
2017 (10)
Retrospective record review of patients in a single 
tertiary referral hospital.
Estimated cost of treating drug susceptible 
pulmonary TB enrolled in a single tertiary referral 
centre.
Provider Median cost = AUD 11,538 (range 5,820 – 
170,119), (year 2012-2014)
Approximately 50% of total costs was 
derived from inpatient hospitalisation 
bed days.
Iran, 2014 
(11)
Cross-sectional study of patients in health centers of 
the Ministry of Health and Ministry of Education.
Calculated the cost of illness of tuberculosis in 
Tehran
Societal The average costs per patient = 28,467,737 
Rials (USD 2,588 dollars) for direct medical 
costs (2011)
The average costs per patient = 1,011,360 Rials 
(92 dollars) for indirect medical costs and
The average costs per patient = 5,533,020 (503 
dollars) Rials for indirect costs.
Overall, average costs per patient was 
35,056,170 Rials.
Most of costs were related to hospital 
costs
Iran, 2017 
(12)
Retrospective study of all new smear positive 
pulmonary TB patients who had been registered 
at the district’s health network between April 
2013 and December 2015 and had successfully 
completed their treatment were entered into the 
study (45 patients). Treatment costs were estimated 
using activity-based costing (ABC) method.
Estimated the cost of smear-positive drug-
susceptible pulmonary tuberculosis treatment of 
the patients in the Azadshahr district, Golestan 
Province, Iran.
Provider The cost of treating a new smear-positive 
pulmonary TB patient = USD 1,409 (Iranian 
Rial, 39,438,260) (year 2015).
Yemen, 2012 
(13)
Prospective cross-sectional study.
Determined the costs associated with tuberculosis 
diagnosis and treatment for the public health 
services and patients in Sana’a, Yemen.
Patient and 
provider
Patient cost: for pulmonary TB treatment = US$ 
108.40 (year 2009)
Provider cost: for pulmonary treatment was US$ 
34.00 (year 2009)
For pulmonary and extra pulmonary TB, 
drug treatment represented 59.3% of the 
total cost to the provider.
The greatest proportionate cost to 
patients for pulmonary TB treatment 
was time away from work (67.5% of the 
total cost), and for extra pulmonary TB 
was laboratory and X-ray costs (55.5%) 
followed by transportation (28.6%).
China, 2019 
(14)
Cross-sectional cost analysis of active TB patients 
who lived in Jingkou District, Runzhou District, 
Dantu District, or Xin District who were diagnosed 
and treated in the No.3 hospital of Zhenjiang City 
from April 2014 to March 2015.
Determined the inpatient service expenditures.
Patient The average total cost to inpatients = Chinese 
Yuan 13007.91 ± 5205.58 (year 2014-2015)
Despite advances in TB insurance 
policies, there were substantial costs 
associated with TB diagnosis and 
treatment. TB patients still face a heavy 
financial burden.
Continue..............
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Table I:  Cost of pTB treatment (Continued....)
Country, 
year
Study population and the conduct of the study Perspective Cost, (currency year) Note
Malaysia, 
2014 (15)
Prospective, incidence-based study design, in a 
government outpatient specialist clinic among all new 
smear positive PTB patients who were diagnosed and 
successfully completed their treatment at the study site 
between March 2010 and February 2011. 
Determined the cost of treatment of smear positive 
pulmonary tuberculosis patients 
Provider 
and patient
The provider cost was = USD 325.35 per 
patient) (year 2010-2011)
The patient cost = USD 401.90 per patient, 
(about 5.7% of study respondents’ annual family 
income.). 
Malaysia, 
2018 (16)
Retrospective and prospective prevalence-based partial 
pharmacoeconomic evaluations.
All types of direct costs were obtained from different 
hospital departments while the indirect costs to the 
patient were estimated by interviewing 30 patients who 
were randomly selected.
Determined the cost of treatment of smear positive 
pulmonary tuberculosis patients in a government 
hospital
Societal The cost of treatment = USD 916/patient (year 
2003)
Tajikistan, 
2010 (17)
Cross-sectional study among new pulmonary TB 
patients enrolled in the DOTS program in 12 districts 
between 2006 and 2007.
Determined the patient costs of TB in the former Soviet 
Union.
Patient Average total illness costs per TB episode = Tajik 
Somonis $1053 ± 1601 (USD 4900 purchasing 
power parity, PPP) (year 2006-2007).
The illness-related costs of an episode of 
TB exceed the per capita GDP of $1600 
PPP about two-and-a-half times.
China, 2010 
(18)
Questionnaire survey of patients currently on treatment 
in eight TB dispensaries in two provinces and in-depth 
interviews with providers at the facilities.
Measured patient expenditure on additional drugs and 
tests in public services where tuberculosis (TB) drugs 
are supplied for free.
Patient Cost to patients of various drugs and tests 
prescribed/ month = Chinese Yuan 287 (USD 
40)
For patients below the poverty line, 
drug and test expenditure was 1.85 
times their average household monthly 
income.
Ethiopia, 
2016 (19)
Cross-sectional cost-of-illness analysis conducted 
between September to November 2015 among 576 
randomly selected adult TB patients who were on 
directly observed treatment in 27 public health facilities 
in Addis Ababa, Ethiopia.
Determined treatment cost of adult TB patients on 
DOTs.
Patient Direct (Out-of-Pocket) mean cost = $123.00 (± 
58.8) (year 2015).
Indirect (loss income) mean cost = $54.26 (± 
43.5) (year 2015).
Despite the availability of free-of-charge 
anti-TB drugs, TB patients were suffering 
from out-of-pocket payments with 
catastrophic consequences.
Ethiopia, 
2018 (20)
Longitudinal study among new TB cases from January 
2015 through June 2016 in 10 woredas (districts) of 
southwestern Ethiopia. 
Direct out-of-pocket, payments, and lost income 
(indirect cost) were solicited from patients during the 
first 2 months and at the end of treatment. Assessed pre- 
and post-diagnosis costs to TB patients.
Patient Direct out-of-pocket expenses during the pre-
diagnosis periods amount to median (IQR) of 
US$21.64 (10.23-48.31) (year 2015).
Direct out-of-pocket expenses during the post-
diagnosis periods respectively amount to median 
US$35.02 (0-70.04), (year 2015). 
China, 2016 
(21)
Retrospective review of data from the baseline survey of 
the China Government – Gates Foundation TB Phase II 
program in 2013.
Assessed the incidence, intensity of catastrophic health 
expenditure (CHE) relating to TB care in China.
Patient The incidence of CHE = 66.8 % using the 
household income measure (year 2013)
The incidence of CHE = 54.7 % using non-food 
expenditure (capacity to pay) (year 2013)
Households defined as experiencing 
CHE if their annual expenditure on 
TB care: (a) exceeded 10 % of total 
household income; and (b) exceeded 
40 % of their non-food expenditure 
(capacity to pay)
Indonesia, 
2018 (22)
Cross-sectional study among adult TB and multidrug-
resistant TB (MDR-TB) patients in urban, suburban 
and rural areas of Indonesia who had been treated for 
at least one month or had finished treatment no more 
than one month earlier at primary health centers (PHCs) 
linked with the country’s National TB Program (NTP).
Assessed the costs of treatment and the incidence of 
catastrophic total costs due to TB.
Patient The median (IQR) of total costs incurred by 
households =USD 133 (55–576), (year 2016).
The incidence of catastrophic total costs in all 
TB-affected households was 36% (43% in poor 
households and 25% in non-poor households).
Catastrophic total costs were defined 
as total costs (direct and indirect costs) 
incurred by household that exceed 20% 
of the household’s annual income. 
Households earning below USD 1.9 per 
capita per day was classified as poor 
households.
India, 2018 
(23)
Mixed-method design among TB patients in Puducherry 
district, where there was free care for TB under the 
national tuberculosis program (NTP).
Estimated patient costs during diagnosis and intensive 
phase of treatment and determined the proportion of 
households experiencing catastrophic costs.
Patient The median (IQR) total cost of TB care = USD 
195 (52.1, 492.9), (year 2016)
The median (IQR) direct cost = USD 65.3 (22.3, 
156.5), (year 2016) 
The median (IQR) indirect cost = USD50.2 ((0.9, 
295.1), (year 2016). 
Catastrophic cost was defined as total 
tuberculosis care costs exceeding 20% 
of annual household income. 
Overall, 32.4% of households 
experienced catastrophic costs due to 
TB care.
Burkina Faso, 
2013 (24)
Cross-sectional study of smear positive pulmonary TB 
patients in six rural districts of Burkina Faso between 
the years 2007and 2008.
Determined out-of-pocket expenses (direct costs) 
associated with TB according to the different stages of 
their healthcare pathway.
Patient Median (IQR) direct cost associated with TB 
=USD 101 (53.1, 172.4), (year 2007-2008)
This cost was equal to 2.8 months of household 
income.
A total of 72% of patients incurred 
direct costs during the pre-diagnosis 
stage (i.e. self-medication, travel, 
traditional healers’ services), 95% 
during the diagnosis process (i.e. user 
fees, travel costs to various providers, 
extra sputum smears microscopy 
and chest radiology), 68% during 
the intensive treatment (i.e. medical 
and travel costs) and 50% during the 
continuation treatment (i.e. medical and 
travel costs).
Continue..............
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Table I:  Cost of pTB treatment (Continued....)
Country, 
year
Study population and the conduct of the study Perspective Cost, (currency year) Note
Nigeria, 2013 
(25)
Cross-sectional cost-of-illness study among all new 
adult smear-positive or smear negative pulmonary 
TB patients registered in the three rural hospitals 
between January and August 2011 in southeast 
Nigeria. 
Estimated the comprehensive costs of TB diagnosis 
and treatment (intensive phase) from the patients’ 
perspective in an under-resourced high TB/HIV 
setting. 
Patient The total cost of TB care per household was 
$592 (year 2011); corresponding to 37% of 
median annual household income pre-TB. 
Patient and household costs for TB care 
are potentially catastrophic even where 
services are provided free-of-charge
China, 2016 
(26)
Cross-sectional study of TB cases from three cities 
selected using a stratified cluster sampling method 
in Zhenjiang City, Jiangsu Province in eastern 
China; Yichang City, Hubei Province in central 
China; and Hanzhong City, Shaanxi Province in 
western China.
Direct non-medical costs related to TB treatment 
were collected using in-person interviews.
Patient The median (IQR) non-medical cost = RMB 
1429 (424–2793), (year 2013)
About 20 % of all respondents had their non-
medical costs exceeded 40 % of their non-food 
expenditure, while 37 % reported that these 
costs exceeded 10 % of their annual household 
income. 
The non-medical costs typically include 
payments for transport, accommodation, 
and the cost of nutritional 
supplementation during the treatment 
period.
United States 
of America, 
2012 (27)
Cost analysis of TB outbreak among homeless 
persons using a Homeless Shelter between the years 
2007 and 2011.
Estimated the costs of providing supportive 
resources for 24 patients with TB disease treatment 
during an outbreak-associated cases.
Provider Supportive resources alone to provide successful 
treatment for these 24 patients with TB = 
$204,500 (year 2011)
Costs excluded the costs of health-care 
services.
All 24 cases completed or were 
continuing treatment as of December 
2011
Peru, 2016 
(28)
Cross-sectional prospective study among TB 
patients in the national TB program which included 
interventions such as economic support (cash 
transfers) and social support (household visits and 
participatory community meetings).
Investigated the economic effects of a TB-specific 
socioeconomic intervention among 32 shantytown 
communities in Peru.
Provider Cash transfer total value averaged US$173 
(equal to 3.5% of TB-affected households’ 
average annual income) (year 2015-2015)
Cash transfer mitigated 20% of 
households’ TB-related costs.
The mitigation impact was higher among 
poorer households.
Africa, 2016 
(29)
Cost-of-illness method. Future non-health GDP 
losses were discounted at 3%.
Estimated future gross domestic product (GDP) 
losses associated with TB deaths in the African 
Region for use in advocating for better strategies to 
prevent and control tuberculosis.
Provider The average total non-health GDP loss = Int$66 
872 per tuberculosis death (year 2014)
Tuberculosis deaths in the African Region 
in 2014 decreased the non-health GDP 
by International Dollars (Int$) 50.4 
billion.
Denmark, 
2015 (30)
Retrospective review of national databases. 
Evaluated the economic burden of tuberculosis 
(TB) in Denmark due to health-related costs (health 
system contacts and –procedures, medications) and 
socio-economic parameters (foregone earnings and 
social transfer expenses).
Societal Employment income deficiency was € 11,635 
before vs. € 13,885 after diagnosis. 
Excess health costs in the 2 years around 
diagnosing and treating TB were € 
10,509. 
Cases received an average excess public 
transfer income of € 3,345 before vs. € 
3,121 after diagnosis.
Spouses also had lower income, more 
social transfer, and posed higher health-
related costs than matched controls.
Benin, 2014 
(31).
 
A retrospective cross-sectional study among smear 
positive TB patients ≥15 years old of the selected 
districts who were enrolled
The survey covered the period from onset of 
TB symptoms to the completion of the DOTS 
treatment. 
Patients’ expenses related to examination and 
laboratory tests, consultation fees, drugs, hospital 
care, transport to healthcare providers, services 
provided by traditional healers, food supplements, 
self-medication and traditional remedies. In-kind 
spending was estimated in local currency by the 
patients during the interview
Patient One-half of the households spent over 2.1 
months of their income to care for the person 
with tuberculosis (IQR, 1.0–4.1). The median of 
the direct economic burden was 17.8% (IQR, 
8.4–34.4%) of the annual household income.
The median indirect cost was 131 (IQR, 77–207) 
days lost by the patient because of illness and 
care-seeking and waiting for consultation; 30 
(IQR, 3–87) days were lost by informal caregiver 
and guardian.
United States 
of America, 
2017 (32)
Retrospective electronic record review of 
TB patients in two tertiary hospitals and one 
community hospital, New York. TB cases in 
hospitals which had delayed diagnosis were 
chosen.
Estimated person-hour costs required by infection 
control staff to investigate a single hospital-based 
TB exposure, in two tertiary hospitals and one 
Community hospital in a large health care system in 
metropolitan New York City.
Provider Used 15-20 hours of work per exposure plus 
30 minutes of follow-up for each exposed staff 
member.
Time from admission to isolation 
averaged 3.3 days, with a mean of 41 
staff exposed per patient.
Continue..............
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Table I:  Cost of pTB treatment (Continued....)
Country, 
year
Study population and the conduct of the study Perspective Cost, (currency year) Note
Australia, 
2013 (33).
Retrospective cost analysis study.
Determined the costs of treating TB after a medical 
officer working in a metropolitan New South Wales 
(NSW) neonatal intensive care unit (NICU) was 
diagnosed with active pulmonary tuberculosis (TB). 
Involved 125 neonates, 165 of their relatives and 
122 health care workers. 
Provider The estimated total cost to the hospital for this 
screening investigation = AUD 128 430 (year 
2011).
Cost of time nurses spent on neonatal 
screening cost = AUD 24 489 (year 2011)
Cost of Chest Clinic registered nurses also 
conducted the relative and health care 
worker screening = AUD 14 913.
Cost of neonatologists and paediatricians 
reviewed the neonates at the screening 
and medical review clinics = AUD 19 
059. 
Cost of respiratory physicians interviewed 
and counselled the families of exposed 
neonates at the initial screening clinics = 
AUD 9148.
AUD – Australian Dollar                CHE – Catastrophic Health Expenditure               DOT – Directly Observed Therapy            IQR – Interquartile Range          NTP – National TB Program
PHC – Primary Health Centre         PPP – Purchasing Power Parity             US – United States            USD – United States Dollar
from 17% to more than 60% of the countries’ GDP, 
compared to middle- and low-income countries (9.9% 
to 38% of the countries’ GDP), could be due to the 
absence of highly subsidised national TB programs in 
the high-income countries, in addition to the fact that 
healthcare costs are generally higher in richer countries 
compared to poorer countries. Nonetheless, despite 
the lower costs of pTB treatment in low- and middle-
income countries, people in these still face financial 
difficulties in getting treatment for pTB. Therefore, in 
these countries, apart from determining the cost TB 
treatment per person, studies also focused on how 
the treatment of TB resulted in catastrophic health 
expenditure among the households of TB patients. For 
example, in Tajikistan, illness-related costs of an episode 
of pTB was about two-and-a-half times more than their 
per capita GDP of $1600 purchasing power parity (PPP) 
(19), while in China  among patients who were below 
the poverty line, drug and test expenditure was almost 
twice of their average household monthly income (20). 
In Ethiopia, the mean total cost of pTB illness to patient 
was USD 177, which USD 123 was direct out-of-pocket 
cost to the patients. This direct cost was catastrophic 
for 63% of pTB patients (21). Another study in Ethiopia 
noted that the direct and indirect out-of-pocket costs 
of TB was approximately USD 56 (22). In China, TB 
treatment resulted in 55% of households experience 
catastrophic health expenditure (21); in Indonesia 43% 
of poor households and 25% of non-poor households 
(24) and in India it was 32.4% (25). In Burkina Faso, 
the pTB treatment cost was also high, equivalent to 
2.8 months’ worth of household income (26), while in 
Nigeria one study showed that the median total cost of 
pTB care per household was USD 592; corresponding to 
37% of median annual household income pre-TB (27). 
The abovementioned studies showed that despite the 
availability of highly subsidised or free-of-charge pTb 
treatment, pTB patients can suffer from out-of-pocket 
payments with catastrophic consequences.
As pTB treatment requires frequent visits to the 
healthcare facility, the Out-of-Pocket expenditure 
incurred by the patients for non-medical items could be 
high. For example, in a study in China, it was found 
that about 20 % of all respondents reported that their 
non-medical costs were more than 40 % of their non-
food expenditure, while for 37 % of the respondents, the 
costs exceeded 10 % of their annual household income 
(28).
Treatment of TB requires that the patient is adherent to 
the treatment regime. In order to ensure adherence to 
treatment, some countries provide social assistance to 
TB patients. Social assistance included housing support, 
cash, food, transportation or treatment for TB disease 
by directly observed therapy. These assistance costs 
are high in TB treatment. For an example, in ensuring 
homeless patients complete their pTB treatment, the 
United States Communicable Disease Center (US 
CDC) spent approximately USD 8,520 per person on 
social assistance during an outbreak of TB involving 24 
individuals in a shelter for the homeless (29). In Peru, 
the government gave cash transfer to pTB patients 
in 32 shanty towns, in order to prevent pTB patients 
from experiencing CHE. The total cash transfer was 
equivalent to 3.5% of TB-affected households’ average 
annual income (30).
Treatment of TB affects not only the individual patient 
and his/her contacts, but also the country. Due to the 
prolonged nature of the disease, the productivity of 
the patient and even the country could be negatively 
affected. For example, the average total non-health GDP 
loss was estimated as International Dollars 66,872 per 
tuberculosis death in Africa. As a result, TB deaths in the 
African Region in 2014 decreased the non-health GDP 
by International Dollars 50.4 billion (31). In Germany, 
the mean cost due to loss of productivity per patient 
was estimated as €2,313 in year 2009 (11). Similarly, 
in Denmark, an average employment income deficiency 
was € 11,635 before diagnosis of pTB versus € 13,885 
after diagnosis (32). The study in Benin also showed 
that the median indirect cost was 131 days lost by the 
patient because of illness and care-seeking and waiting 
for consultation; 30 days were lost by informal caregiver 
and guardian (33).
These studies also showed that outbreak management 
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of TB cases used a substantial amount of resources, 
particularly human resource and laboratory tests, as pTB 
outbreak management also includes contact tracing, 
contact screening and provision of post-exposure 
prophylaxis. In circumstances where TB was missed as 
a possible diagnosis, the health care facility involved 
could face calamitous consequences. For example, a 
study showed that an additional workload of almost 
40 hours was required for managing a contact of a 
pTB index-case (34). Another study of a TB case in 
health care facility also described the extensive use of 
resources, in addition to high levels of anxiety for the 
relatives of the patients. In that study, the diagnosis of 
one infected neonatal intensive care unit (NICU) staff 
resulted in the contact tracing and screening of 125 
neonates, 165 relatives of the neonates and 122 health 
care workers (35).
CONCLUSION
The findings in this review illustrate the magnitude of 
economic impact faced by an individual, community 
and country in managing pTB. The costs of treating pTB 
in one individual can be more than half of the country’s 
GDP per capita. Even when the treatment costs are not 
very high because of the availability of highly subsidised 
or free-of-charge treatment, an episode of pTB can 
put the patient’s household into catastrophic health 
expenditure, whereas an outbreak can overwhelm the 
health system’s capacity to carry out daily activities and 
manage the outbreak. Additionally, productivity of the 
individuals affected by the outbreak are reduced, and 
at a macro level this can disrupt the economy of the 
country including trade and travel. 
The most cost-effective way to prevent the economic 
impact of TB or its outbreak is to ensure adequate and 
timely vaccination of the target groups. The unavailability 
of vaccines in several low-income countries must be 
addressed urgently. Additionally, as vaccine hesitancy is 
an additional burden to a persisting problem of vaccine 
unavailability, the realization of the economic impact of 
VPD should encourage vaccine-hesitant individuals to 
reconsider their stance on vaccination. 
The major limitation to this review is that the studies 
were not nationally representative. Instead they were 
conducted in one or several health facilities, or in one 
or several parts of a country. Therefore, the results of the 
studies could only be limited to those study sites and 
not generalizable. It is recommended that a nationwide 
costing study is conducted especially in countries where 
TB incidence is high. 
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